Introduction {#s0005}
============

The transplanted ureter is highly susceptible to a compromised blood supply, as after explantation the blood supply to the ureter is exclusively from the renal pelvic arteries, which run in the peri-ureteric adventitia and might be injured during explantation. Therefore, ureteric problems outnumber all other surgical complications that occur after renal transplantation (RTX), e.g. lymphocele formation, bleeding, or transplant vessel thrombosis. Stenosis and leakage of the ureter occur in about 5% of cases, while ureteric necrosis is a rare event (0.5%) [@b0005; @b0010; @b0015].

Ureteric complications mostly appear in the initial 3 months after RTX. If detected in time and treated adequately, they do not impair graft or patient survival [@b0015; @b0020; @b0025]. There are many options for treating transplant ureteric stenosis. Minimally invasive methods include insertion of a ureteric stent (JJ or J) and percutaneous nephrostomy (PNS), which are usually used to overcome acute renal insufficiency rather than providing long-term relief. Also, minimally invasive antegrade balloon dilatation (BD) has been described as a promising alternative to open re-operation of a stenosed renal transplant ureter [@b0030; @b0035; @b0040; @b0045; @b0050; @b0055; @b0060; @b0065; @b0070; @b0075].

The RTX programme at the University Hospital Duesseldorf started in 1968, and is one of the largest programmes in Germany, having transplanted 2347 kidneys (2011 deceased donors/336 living donors) until the end of 2010, with \>100 annual RTX over the past 5 years. During the study period, 262 RTX were performed (200 from deceased donors, 62 from living donors). Because of the intensified cooperation between surgeons and urologists in RTX at our institution since September 2008, retrograde BD (RBD), performed by staff in the Department of Urology, became part of the increased options for treating of transplant ureteric stenosis. All patients presenting with a ureteric stenosis after RTX received a first therapeutic approach by RBD. In this retrospective study we aimed to evaluate the outcome of RBD in renal transplant recipients who developed ureteric stenoses. Furthermore, we compared our findings of RBD with a review of previous reports, where only the percutaneous, antegrade approach was described, for the optimal treatment of transplant ureteric stenosis.

Patients and methods {#s0010}
====================

We retrospectively analysed all renal transplant recipients who underwent RBD of a stenosed transplant ureter in our department. Due to the new implementation of this technique, interventions were between September 2008 and March 2011. The technique of RTX used at our institution is an extraperitoneal approach with end-to-side anastomosis of the renal vessels with the recipient's external iliac vein and artery, and an extravesical ureteric anastomosis (full-thickness anastomosis of the spatulated ureter with the recipients bladder, nonantirefluxive). As a study on the effect of ureteric stent insertion vs no stenting in RTX ended in December 2009, and found a favourable effect of transplant ureteric stenting, a ureteric stent was routinely placed during RTX from 2010. Patients were followed regularly, including transplant ultrasonography done by hospital or external nephrologists. When postrenal obstruction was suspected, patients were treated in cooperation with the Department of Urology.

RBD of ureteric stenosis was done under general anaesthesia and antibiotic prophylaxis. Briefly, the transplant ureteric orifice was identified by transurethral cystoscopy. After retrograde transplant ureterography and exact localisation of the stricture site, a guidewire (ZipWire™ or Sensor™, Boston Scientific, Pierreux, France) was advanced to the transplant renal pelvis. The balloon dilation system (Cook Urological Inc., Spencer, Indiana, USA) was introduced into the ureter over a guidewire and the balloon extended with a 1:1 mixture of contrast medium/sodium chloride to the maximum diameter (6 mm/18 F) and maximum pressure (2.0 MPa) at the stricture site. Thus, the stricture was initially seen as a hourglass-like impression of the dilated balloon, which disappeared on maximum balloon expansion. Then the dilator was kept in place for 3--5 min. As we wanted to apply as little contrast medium as necessary in this retrograde approach, and as in low-volume retrograde ureterography a stenosis might be not detected after dilatation of the stricture, we slid the inflated balloon of the dilator through the rest of the transplant ureter to assure its patency over the whole length. At the end of the RBD procedure, a JJ stent (Visiostar Standard™, 7 F/22 cm, Urovision, Germany) was inserted, the cystoscope was withdrawn, and a 16 F Foley catheter was placed for 1--3 days ([Fig. 1](#f0005){ref-type="fig"}). The stent was removed with a flexible cystoscope under local anaesthesia at 14--21 days after the intervention. After this, the follow-up consisted of regular ultrasonographic assessment and creatinine assay in the Department of Nephrology. When there was an increase in creatinine level and/or dilatation of the transplant renal pelvis, the patient was re-evaluated for further intervention (stent insertion, repeated RBD, open operation).

We also searched PubMed and Medline for articles on the treatment of transplant ureteric stenosis and evaluated our findings in the light of this overview.

Results {#s0015}
=======

Between September 2008 and March 2011, eight recipients (five men and three women) of renal transplants (seven first transplants, one third transplant) from one living and seven deceased donors, were treated with single or repeated RBD of the stenosed transplant ureter. The median (range) age at RTX was 55 (38--69) years. Demographic data, underlying diseases and transplant-related data are summarised in [Table 1](#t0005){ref-type="table"}. There were no complications from the RBD.

Half of the recipients were treated with one RBD and the other half with two, for six distal, one middle and one proximal ureteric stenosis. The median (range) time from RTX to first RBD was 4.5 (2.5--11.4) months, and the median time from unsuccessful first RBD to final operative management was 2.8 (0.7--7.0) months, with a median follow-up after definitive management of 4.1 (1.9--6.6) months. The median (range) follow-up after RTX was 11.4 (7.3--25) months ([Table 2](#t0010){ref-type="table"}).

Long-term success was achieved in one recipient only. In this patient a uretero-ureterostomy between the native and the transplant ureter had been formed 4 days after the RTX, because the initial vesico-ureteric anastomosis was stenosed. This uretero-ureterostomy also strictured and therefore was treated with RBD after 5.1 months. Five transplant ureters re-stenosed and had to be re-operated on with transplant ureter neo-implantation into the bladder (three) or replacement of the transplant ureter with ileum (two). For two recipients the success remains unclear. In one patient with reduced transplant function not related to ureteric stenosis, immunosuppression had to be stopped and the graft explanted, as the recipient suffered from repeated severe infections including cytomegalovirus pneumonia. Another recipient was treated recently and the stent was still in place at the time of this report.

Discussion {#s0020}
==========

Stenosis of the transplant ureter mostly occurs at the site of ureteric anastomosis and has been described in 0.5--5% of adult [@b0005; @b0010; @b0015; @b0020] and 3--10% of paediatric recipients [@b0080; @b0085; @b0090]. The type of ureteric anastomosis with the recipient bladder (Lich-Gregoir, Politano-Leadbetter) does not affect the occurrence of ureteric stenosis [@b0095]. Anastomosis of the transplant ureter with the recipient's native ureter was not found to increase the risk of ureteric stenosis by some authors [@b0100], while others detected a greater risk compared with anastomosis with the recipient's bladder [@b0105]. In paediatric recipients, PUV were found to be associated with ureteric stenosis after RTX, possibly because remodelling of collagen I/III also affects the ureteric anastomosis site of the transplant ureter in these children [@b0090]. A very rare cause of ureteric stenosis in paediatric recipients might be a BK virus infection; to date, in one case report this was found to be the underlying cause [@b0110]. In the recipients at our centre, regular controls for BK virus in the peri- and postoperative phase of RTX are part of the routine assessments. In one recipient 60,000 copies of BK virus were detected once, but as this was several months after the formation of a ureteric stenosis, and 5 weeks after RBD of the strictured ureter without BK virus detection immediately before and afterwards, BK virus infection as the underlying cause for the ureteric stricture appears unlikely.

Possible risk factors for adult recipients are donor age \>65 years, delayed graft function, the existence of more than two transplant arteries or a double ureter, and the duration of organ transport (cold ischaemic time) [@b0015; @b0020; @b0115; @b0120; @b0125]. In the present patients, two donor kidneys which developed ureteric strictures had a double ureter, and one was found to have multiple arteries. As the anatomy of a donor organ cannot be changed, the implanting surgeon/urologist should be aware of these risk factors for ureteric stenosis during the operation. Moreover, this should lead to a closer follow-up in the early phase after RTX to ensure timely detection of possible ureteric complications. Insertion of a ureteric stent during RTX significantly prevents ureteric stenosis and (as it also prevents complications due to ureteric leakage) should be used routinely in all RTX [@b0025]. Therefore, we have started to insert ureteric stents in all RTX procedures.

Many treatment options have been described for transplant ureteric stenosis, ranging from minimally invasive procedures to open re-operation. Generally, PNS or stenting can be done but usually provide no long-term relief. Nevertheless, in selected cases ureteric stenting might provide a definitive solution [@b0130], as can the insertion of a subcutaneous artificial ureter (Detour™, Mentor-Porges, Le Plessis Robinson, France), which has been described for about 20 renal transplant recipients so far [@b0135; @b0140]. Another minimally invasive method is endoscopic transplant ureterotomy, which has been reported for only ≈20 cases. The success rate was \>50% [@b0145; @b0150] but there are too few cases to recommend this as a general approach.

BD of the ureter is a minimally invasive approach for treating transplant ureteric stenosis, and an alternative to open re-operation with re-implantation of the transplant ureter, a new anastomosis of the native ureter with the renal transplant pelvis, performing a Boari flap/psoas hitch or replacement of the transplant ureter with ileum [@b0155; @b0160; @b0165; @b0170]. Over the past 23 years, experience with ≈200 cases of BD of a stenosed transplant ureter has been reported ([Table 3](#t0015){ref-type="table"}). Interestingly, all studies used the technique of antegrade BD via an initially placed PNS. Complications were not severe and mostly consisted of limited haematuria and/or UTI. A half to two-third of these interventions were reported to have been successful after single or repeated BD, with a tendency to a higher success rate the earlier the BD was performed after RTX [@b0030; @b0035; @b0040; @b0045; @b0050; @b0055; @b0060; @b0065; @b0070; @b0075].

The most important conclusions to be drawn from previously published data are: (i) BD within 3 months after RTX is more successful than later treatment; (ii) if initial BD fails, the success rate of further dilatation is \<25%; (iii) BD does not compromise subsequent ureteric operations that might become necessary if BD fails to achieve long-term relief.

In our small study, the first on RBD, the time after RTX was \>10 weeks. This might be why the success rate was very low, even though the one patient successfully treated with BD had been treated 5.1 months after RTX. Also, our study is the first to evaluate the retrograde approach to transplant ureter BD. The present limited success rate compared to antegrade BD might be due to as yet unidentified factors of the chosen approach. Overall, our experience confirms the findings published in other series; if a first BD fails, further BD does not improve the outcome. Therefore, we have changed our algorithm for ureteric stenosis after RTX. An initial attempt with RBD is only offered to recipients with early transplant ureteric stenoses (\<10 weeks); if this attempt fails, open re-operation is our therapy of choice. Nevertheless, depending on the individual setting, BD might be tried in recipients developing stenosis later after RTX if risk factors for ureteric transplant stenosis are favourable (low donor age, single donor ureter, single transplant artery, short cold ischaemic time). We are well aware that the limitations of this study are the retrospective approach and the small sample size.

In conclusion, our findings of this first study on RBD of transplant ureteric stenoses confirm the results published by others: late treatment of ureteric stenosis is often unsuccessful, irrespective of the approach (retrograde and antegrade). Recipients developing transplant ureteric stenosis should be followed closely. Early-stage treatment with single BD and subsequent open operation in case of unsuccessful BD should be offered within 10--12 weeks after RTX. In case of late occurrence (\>12 weeks after RTX), re-operation and neo-implantation of the transplant ureter should be considered as the first choice.

![Retrograde balloon dilation. Stenosis of the distal transplant ureter of a renal transplant with 2 ureters (second ureter not opacified). The right image shows successful dilation with full expansion of the balloon.](gr1){#f0005}

###### 

Summary of demographic data, underlying diseases, transplant-related data, and complication management. RTX: renal transplantation; ADPKD: autosomal polycystic kidney disease; GN: glomerulonephritis; d = post transplant day

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      Patient   Sex   Age at RTX (years)   Underlying disease           Number of RTX   Living (LD)/deceased donor (DD)   Stent during RTX   Stricture site               Number of dilations                  Success   Problem (P)/definitive management (DM)
  --- --------- ----- -------------------- ---------------------------- --------------- --------------------------------- ------------------ ---------------------------- ------------------------------------ --------- --------------------------------------------------------------------------------------------
  1   GT        m     43                   ADPKD                        1               LD                                No                 Distal ureteral/neo-ostium   1                                    Yes       **P**: transplant ureter necrosis ureteroureterostomy d4\
                                                                                                                                                                                                                         **DM**: dilation

  2   ZW        m     38                   Fam. cystic kidney disease   1               DD                                No                 Distal ureteral/neo-ostium   2[a](#tblfn1){ref-type="table-fn"}   No        **P**: 2 transplant ureters implanted separately\
                                                                                                                                                                                                                         **DM**: neoimplantation of both ureters

  3   AS        m     75                   Nephrosclerosis              1               DD                                Yes                Distal ureteral/neo-ostium   2                                    ?         **P**: poor graft function, recurrent CMV-pneumonia/sepsis\
                                                                                                                                                                                                                         **DM**: transplant nephrectomy

  4   HW        f     66                   ?                            3               DD                                Yes                Prox. ureteral               1                                    No        **DM**: ileal interposition

  5   PH        m     44                   Mesangioprolif. GN           1               DD                                Yes                Middle 1/3                   1                                    No        **DM**: neoimplantation of transplant ureter

  6   GA        f     44                   ?                            1               DD                                Yes                Distal ureteral/neo-ostium   1                                    No        **DM**: replacement of ureter with ileum

  7   CW        f     68                   Nephrocalcinosis             1               DD                                Yes                Distal ureteral/neo-ostium   2                                    No        **DM**: neoimplantation of Transplant ureter

  8   KH        m     69                   ?                            1               DD                                Yes                Distal ureteral/neo-ostium   2                                    Pending   **P**: incomplete duplex ureter leakage\
                                                                                                                                                                                                                         **DM**: neoimplantation of 1 of the 2 ureters d 42, sec. ureter could be left as implanted
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only one of the two ureters could be dilated in the first attempt, the second ureter was dilated 10 days later. DM, definitive management; ADPKD, autosomal polycystic kidney disease; CKD, cyctic kidney disease; GN, glomerulonephritis; LD, living donor; DD, deceased donor; DU, distal ureteric; neo-o, neo-ostium; mesangiop GN, mesangioproliferative glomerulonephritis; CMV, cytomegalovirus.

###### 

Time until first dilation, definitive management, and follow-up after RTX. ∗ = case with success of first dilation and pending case excluded.

                         Patient initials   Interval between RTX and 1st dilation (months)   Interval between RTX and definitive management (months)   Interval between 1st dilatation and definitive management (months)   Follow-up after RTX (months)   Follow-up after 1st dilation (months)   Interval between definitive management and last follow-up
  ---------------------- ------------------ ------------------------------------------------ --------------------------------------------------------- -------------------------------------------------------------------- ------------------------------ --------------------------------------- -----------------------------------------------------------
  1                      GT                 5.1                                              Success                                                   Success                                                              21.3                           16.2                                    Success
  2                      ZW                 11.4                                             18.4                                                      7.0                                                                  25.0                           13.6                                    6.6
  3                      AS                 5.2                                              8.2                                                       3.0                                                                  9.6                            4.4                                     1.4
  4                      HW                 3.0                                              3.7                                                       0.7                                                                  11.4                           8.4                                     7.7
  5                      PH                 4.0                                              6.5                                                       2.5                                                                  12.5                           8.5                                     6.0
  6                      GA                 4.5                                              7.9                                                       3.4                                                                  9.8                            5.3                                     1.9
  7                      CW                 2.5                                              5.2                                                       2.7                                                                  7.3                            4.8                                     2.1
  8                      KH                 8.2                                              Pending                                                   Pending                                                              9.4                            1.2                                     Pending
                                                                                                                                                                                                                                                                                                   
  Median time (months)                      4.5^∗^                                           7.2^∗^                                                    2.8^∗^                                                               11.4^∗^                        8.4^∗^                                  4.1^∗^

###### 

Publications on dilation of transplant ureter stenosis after renal transplantation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                 Year of publication   Number of transplants                  Number of ureteral strictures treated by balloon dilation                 Interval between transplantation & balloon dilation   Site of stricture   Success rate pts (%)       Complications
  ------------------------- --------------------- -------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------- ------------------- -------------------------- ------------------------------------------------
  Voegeli [@b0030]          1988                  ?                                      14[a](#tblfn2){ref-type="table-fn"}                                       nn                                                    nn                  11/14 (79%)                None

  Lojanapiwat [@b0035]      1994                  692                                    21[a](#tblfn2){ref-type="table-fn"}^,^[b](#tblfn3){ref-type="table-fn"}   14 × \<3 months\                                      17 UVJ\             12/21 (57%)\               "no perforation of ureter/pelvic area"
                                                                                                                                                                   7 × \>3 months                                        4 UPJ               \<3 months: 10/14 (71%)\   
                                                                                                                                                                                                                                             \>3 months: 2/ 7 (29%)     

  Fontaine [@b0040]         1997                  ?                                      44[a](#tblfn2){ref-type="table-fn"}                                       13 × \<3 months\                                      nn                  13/44 (30%)\               38% UTI\
                                                                                                                                                                   31 × \>3 months                                                           \<3 months: 8/13 (62%)\    14% limited hematuria
                                                                                                                                                                                                                                             \>3 months: 5/31 (16%)     

  Peregrin [@b0045]         1997                  1074                                   23[a](#tblfn2){ref-type="table-fn"}                                       13 × \<3 months\                                      nn                  10/23 (43%)\               Limited hematuria = "most common complication"
                                                                                                                                                                   10 × \>3 months (2 × \>years)                                             \<3 months: 6/13 (46%)\    
                                                                                                                                                                                                                                             \>3 months: 4/10 (40%)     

  Collado [@b0050]          1998                  472                                    18[a](#tblfn2){ref-type="table-fn"}                                       8 months (1--30)                                      16 UVJ\             7/18 (39%)\                None
                                                                                                                                                                                                                         1 UPJ\              \<3 months: 4/5 (80%)\     
                                                                                                                                                                                                                         1 UPJ & UVJ         \>3 months: 3/13 (23%)     

  Yong [@b0055]             1999                  ?                                      9[a](#tblfn2){ref-type="table-fn"}                                        6 × \<3 months (1--2.5)\                              8 UVJ\              8/9 (89%)\                 None
                                                                                                                                                                   3 × \>3 months (4--5)                                 1 UPJ               \<3 months: 6/6 (100%)\    
                                                                                                                                                                                                                                             \>3 months: 2/3 (66%)      

  Kristo [@b0060]           2003                  622                                    9[a](#tblfn2){ref-type="table-fn"}                                        median 7 months (3--122)                              9 UVJ               9/9 (100%)                 None

  Bachar [@b0065]           2004                  422                                    21[a](#tblfn2){ref-type="table-fn"}^,^[c](#tblfn4){ref-type="table-fn"}   1.5--30 months\                                       19 × UVJ\           13/21 (62%)\               38% UTI\
                                                                                                                                                                   early group 1.5 months\                               2 × UPJ\            7/12 (58%)\                hematuria -- most common
                                                                                                                                                                   late group 10.5 months                                1 × mid ureter      6/9 (66%)                  

  Juaneda [@b0070]          2005                  1000                                   45[a](#tblfn2){ref-type="table-fn"}                                       6.8 months (0.01--64)                                 nn                  20/45 (45%)                2 × sepsis with subsequent graft loss\
                                                                                                                                                                                                                                                                        15 × steroid sensitive AR

  Bromwich [@b0075]         2006                  207                                    9[a](#tblfn2){ref-type="table-fn"}                                        17 months (1--276)                                    3 × UVJ\            4/9 (45%)                  None
                                                                                                                                                                                                                         5 × UPJ\                                       
                                                                                                                                                                                                                         1 UPJ & UVJ                                    

  This study (retrograde)   2011                  262[d](#tblfn5){ref-type="table-fn"}   8                                                                         4.5 months (3--11)                                    6 × UVJ\            1/8 (12%)                  none
                                                                                                                                                                                                                         1 × middle\                                    
                                                                                                                                                                                                                         1 × UPJ                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UVJ = uretero-vesical junction; UPJ = uretero-pelvic junction; AR = acute rejection; UTI = urinary tract infection; nn = not named/data missing.

Antegrade (percutaneous) dilation via transplant nephrostomy

Dilation not with balloon but with ureteral stents.

11 of these patients were referred from other centres.

Number of renal transplantations at the Heinrich Heine University Hospital during the study period from 10/2008 to 02/2011.
